Z-DEVD-FMK 是一种特异性的不可逆的 caspase-3 抑制剂,IC50 为 18 μM。
Description | Z-DEVD-FMK is a specific and irreversible caspase-3 inhibitor with IC50 of 18 μM. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
| ||||||||||||||||
In Vitro | N27 cells are exposed to MPP+ in the absence or presence of 50 μM Z-DIPD-FMK or 100 μM Z-DEVD-FMK or 50 μM Z-LEHD-FMK and then caspase-9 and caspase-3 enzymatic activities are determined by enzymatic assay at 12 and 24 h following exposure, respectively. Exposure to 300 μM MPP+ for 24 h in N27 cells results in an approximately 2.5-fold increase in caspase-3 enzyme activity. MPP+-induced increases in caspase-3 enzyme activity are significantly blocked by 50 μM Z-DIPD-FMK, 100 μM Z-DEVD-FMK, and 50 μM Z-LEHD-FMK[1]. | ||||||||||||||||
In Vivo | Early Z-DEVD-FMK (160 ng) treatment improves motor and cognitive function after traumatic CNS injury induced by severe controlled cortical impact (CCI) in the mouse[2]. Treatment with Z-DEVD-FMK (160 ng) significantly improves neurological outcome when compared with traumatized animals treated with DMSO vehicle (p<0.01)[3]. | ||||||||||||||||
Solvent & Solubility | In Vitro: DMSO : ≥ 33.33 mg/mL (49.85 mM) * "≥" means soluble, but saturation unknown. Preparing Stock Solutions
* Please refer to the solubility information to select the appropriate solvent. In Vivo:
| ||||||||||||||||
References | |
温馨提示:因厂家更改产品包装、产地或者更换随机附件等没有任何提前通知,且每位咨询者购买情况、提问时间等不同,为此以下回复仅对提问者3天内有效,其他网友仅供参考!若由此给您带来不便请多多谅解,谢谢!
服务热线
0771-3293894